The board has recommended a dividend of 15 (10%) per cent for the FY 2004-05.

Total income was up 84.03 per cent at Rs 83.22 crore (Rs 45.22 crore), including a 61.95 per cent increase in Exports.

For 2004-05, the company posted a 244.64 per cent gain in net profit to Rs 26.48 crores (Rs 7.69 crore) on a 43.79 per cent rise in total income to Rs 239.45 crore (Rs 166.52 crore).

The revenue from Exports during the year was up by 60% at Rs 108.80 crore (Rs 67.93 crore).

At a consolidated level, including first year revenues from Wholly owned subsidiary of the Company from US, the company posted net profit of Rs 25.66 crore on total income of Rs 239.54 crores for the year.

The EPs of the Company for the year stood at Rs. 16.17 ( Rs. 5.24 )

Mr V.KMehta, Jt. Managing Director, told newspersons that the company’s 150 crores expansion plans is at an advanced stages of completion and with the new facilities coming into operations our total capacities will have a sea jump and we expect the revenues in the FY2005-06 grow substantially.”

Mr Mehta said the company has established its base in US where Us subsidiary is in operation for the last two years and similarly we are also entering the regulated markets of Japan and Australia and we are also opening up a office in China to see the Export potential of our products

The company, six dedicated facilities which are running at full capacities . Ind-Swift laboratories limited a one of the largest manufacturers of the API and advanced intermediates in Domestic and International market has already builtup World Class manufacturing and Research facilities . It possesses large scale capacities for all the Complex molecules where it is present. Over the last few years, ISLL has shifted its focus to complex molecules and development of non - infringing processes.

The company’s expansion plans includes setting up of three dedicated facilities, a new R&D center to facilitate ISLL's entry into regulatory markets, particularly of US & Europe, with filing of 25 DMFs by 2007-08, as drugs worth US$ 84 billion go off patent by 2008. Further the company expects the number of global companies with which it has long term tie up to double in next 2-3 years.

The Company has already started exporting its products to the soft regulated and non-regulated markets and as per the Company sources a huge expansion is underway to strengthen Company’s position in the regulated markets. ISLL has also started the process of regulatory filings – it has already filed process patents for two of its products and is in the process of developing non-infringing processes for around five to six new molecules.

The company has launched and built global scale capacities in several high potential molecules like Clarithromycin, Fexofenadine and Atorvastatin – ISLL is in fact the largest producer of Clarithromycin (around 23% of global capacity) and Fexofenadine in the World after the innovators.

The Company has already tied up with four US companies, which figure among the top 15 Companies in the US, for supply of its products.

The company is also among the first few players to launch other complex products like Clopidogrel, Candesartan, Atorvastatin, Pioglitazone and Citalopram. ISLL is in fact the only company in the world apart from the innovator (Abbott) to have developed Clarithromycin granules, and was also the first to develop Roxithromycin granules. The R&D of the Company is ready with four new patents . These are patents for non - infringing processes of an Anti-Diabetic, Cardiovascular, Anti-Histamine & Antibiotic drug respectively.

Besides developing new molecules and building large capacities for the same, ISLL has also been actively building a channel for marketing in the targeted markets. While the company is already well entrenched in most unregulated markets, it is in talks with several players in Europe and US for supply contracts. ISLL has already tied up with a couple of companies in Europe, while discussions are on with several generic players for the US markets as well for the supply of various products post patent expiry.